HUBBARD, Ohio--(BUSINESS WIRE)--NanoLogix (PINK OTC Markets: NNLX), an innovator in the accelerated detection and identification of microorganisms, announces the current 300 patient trial of NanoLogix GBS (Group B Streptococcus) Quick Tests is ongoing at the University of Texas Health Science Center (UTHSC) in Houston. NanoLogix anticipates initial filings for GBS Quick-Test FDA approval following final publication of the GBS trial results. In addition, this month UTHSC Houston plans to expand its evaluation of NanoLogix Quick Tests, concurrent with the GBS trial, to include the superbug MRSA (formally known as Methicillin-resistant Staphylococcus aureus), with E.Coli and Pseudomonas to follow in early 2011. For further information on the GBS trial please visit the UTHSC - Houston Newsroom at: http://www.uthouston.edu/media/newsreleases/nr2010/index.htm?id=2434326
